Table 3: Phase II/III studies of chemotherapeutic agents in melanoma.

Study reference No. of patients eligible for analysis (followup) TNM stage Treatment arm Median followup at time of reporting (yrs) OS Veronesi et al. 1982 [96] 931 II/III DTIC BCG DTIC + BCG Obs 5 NS Lejeune et al. 1988 [97] 325 I, IIA, IIB DTIC Levamisole placebo 4 NS Fisher et al. 1981 [98] 181 II/III CCNU Obs 3 NS Koops et al. 1998 [99] 632 II/III Isolated limb perfusion + hyperthermia Obs 6.4 BS

Keys: NS—not significant; S—significant; HR—hazard ratio.